Close Menu

NEW YORK – In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health's Oncotype DX appear to benefit significantly from added chemotherapy.

Investigators led by the trial's PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the European Society for Medical Oncology 2019 Congress.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
13

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Nov
18
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.